Erratum: Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014 (Annals of the American Thoracic Society (2018) 15 (817-826) DOI: 10.1513/AnnalsATS.201709-727OC);Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014

Annals of the American Thoracic Society

Volumn 15, Issue 7, 2018, Pages 817-825

  Adjemian, Jennifer ^a,b   Olivier, Kenneth N ^c   Prevots, D Rebecca ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b U S PUBLIC HEALTH SERVICE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cystic fibrosis; Epidemiology; Nontuberculous mycobacteria; Pulmonary

Indexed keywords

MACROLIDE;

ADULT; ARTICLE; ASPERGILLUS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIUM ISOLATION; BODY MASS; CHILD; FEMALE; FORCED EXPIRATORY VOLUME; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; LUNG FIBROSIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM COMPLEX; PREVALENCE; PULMONARY NONTUBERCULOUS MYCOBACTERIA; RISK FACTOR; STENOTROPHOMONAS MALTOPHILIA; TREND STUDY; UNITED STATES; ADOLESCENT; CLINICAL TRIAL; CYSTIC FIBROSIS; FOLLOW UP; ISOLATION AND PURIFICATION; LUNG DISEASE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; REGISTER; RETROSPECTIVE STUDY; SPUTUM; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; SPUTUM; UNITED STATES; YOUNG ADULT;

EID: 85049688057     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/ANNALSATS.159ERRATUM     Document Type: Erratum

References (37)

1. Adjemian J, Olivier KN, Seitz A, Holland S, Prevots R. Prevalence of pulmonary nontuberculousmycobacterial infections amongU.S.Medicare beneficiaries, 1997-2007. Am J Respir Crit Care Med 2011;183:A2400.
2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
3. [Published erratum appears in Am J Respir Crit Care Med 175:744-745.]
4. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, BloskyMA, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.AmJRespirCritCareMed 2010;182:970-976.
5. Falkinham JO III. Nontuberculous mycobacteria in the environment. Clin Chest Med 2002;23:529-551.
6. George KL, Parker BC, Gruft H, Falkinham JO III. Epidemiology of infection by nontuberculous mycobacteria. II. Growth and survival in natural waters. Am Rev Respir Dis 1980;122:89-94.
7. Falkinham JO III, Parker BC, Gruft H. Epidemiology of infection by nontuberculous mycobacteria. I. Geographic distribution in the eastern United States. Am Rev Respir Dis 1980;121:931-937.
8. Strollo SE, Adjemian J, Adjemian MK, Prevots DR. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc 2015;12:1458-1464.
9. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014; 190:581-586.
10. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-1891.
11. Adjemian J, Frankland TB, Daida YG, Honda JR, Olivier KN, Zelazny A, et al. Epidemiology of nontuberculous mycobacterial lung disease and tuberculosis, Hawaii, USA. Emerg Infect Dis 2017;23:439-447.
12. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 2016;13: 1173-1179.
13. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706.
14. Cavalli Z, Reynaud Q, Bricca R, Nove-Josserand R, Durupt S, Reix P, et al. High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis. J Cyst Fibros 2017;16: 579-584.
15. Leung JM, Olivier KN. Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis. Curr Opin Pulm Med 2013;19:662-669.
16. Tomashefski JF Jr, Stern RC, Demko CA, Doershuk CF. Nontuberculous mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med 1996;154:523-528.
17. Smith MJ, Efthimiou J, Hodson ME, Batten JC. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984;39:369-375.
18. Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005;171: 621-626.
19. Haverkamp MH, van Wengen A, de Visser AW, van Kralingen KW, van Dissel JT, van de Vosse E. Pulmonary Mycobacterium abscessus: a canary in the cystic fibrosis coalmine. J Infect 2012;64:609-612.
20. Jang MA, Kim SY, Jeong BH, Park HY, Jeon K, Kim JW, et al. Association of CFTR gene variants with nontuberculous mycobacterial lung disease in a Korean population with a low prevalence of cystic fibrosis. J Hum Genet 2013;58:298-303.
21. Colombo RE, Hill SC, Claypool RJ, Holland SM, Olivier KN. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010;137:629-634.
22. Kim RD, Greenberg DE, Ehrmantraut ME,Guide SV, Ding L, Shea Y, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066-1074.
23. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ruoss SJ. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006;130:995-1002.
24. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006;130:1441-1447.
25. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, et al.; ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 2014;43:125-133.
26. Esther CR, Jr., Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010;9:117-123.
27. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, et al.; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of nontuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016;71:i1-i22.
28. Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013;12: 74-80.
29. Roux AL, Catherinot E, Ripoll F, Soismier N,Macheras E, Ravilly S, et al.; Jean-Louis Herrmann for the OMA Group. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009;47:4124-4128.
30. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, et al.; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
31. Adjemian J, Olivier KN, Seitz AE, Falkinham JO 3rd, Holland SM, Prevots DR. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 2012;186:553-558.
32. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One 2014;9:e91879.
33. Falkinham JO III, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other mycobacteria in drinking water distribution systems. Appl Environ Microbiol 2001;67:1225-1231.
34. United States Department of Agriculture. Soil survey of the territory of Hawaii: islands of Hawaii, Kauaii, Lanai, Maui, Molokai, and Oahu. Soil Survey Series 1955;1939:1-64.
35. Hennessee CT, Seo JS, Alvarez AM, Li QX. Polycyclic aromatic hydrocarbon-degrading species isolated from Hawaiian soils: Mycobacterium crocinum sp. nov., Mycobacterium pallens sp. nov., Mycobacterium rutilum sp. nov., Mycobacterium rufum sp. nov. and Mycobacterium aromaticivorans sp. nov. Int J Syst Evol Microbiol 2009;59:378-387.
36. Bouso JM, Burns JJ, Amin R, Livingston FR, Elidemir O. Household proximity to water and nontuberculous mycobacteria in children with cystic fibrosis. Pediatr Pulmonol 2017;52:324-330.
37. Kazda J, Pavlik I, Falkinham JO III, Hruska K. The ecology of mycobacteria: impact on animal's and human's health. Berlin: Springer Science & Business Media; 2010.